Microchip Technology 10-Q 2022-12-31

Filed 2023-02-02. 8 sections, 320K characters. Original on sec.gov · Markdown · JSON

Cover and table of contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2022

OR

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

Commission File Number: 0-21184

mchp-20221231_g1.jpg

MICROCHIP TECHNOLOGY INCORPORATED

(Exact Name of Registrant as Specified in Its Charter)

Delaware86-0629024
(State or Other Jurisdiction of Incorporation or Organization)(IRS Employer Identification No.)

2355 W. Chandler Blvd., Chandler, AZ 85224-6199

(Address of Registrant's Principal Executive Offices)

(480) 792-7200

(Registrant's Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each ClassTrading Symbol(s)Name of Each Exchange on Which Registered
Common Stock, $0.001 par valueMCHPNASDAQ Stock Market LLC
(Nasdaq Global Select Market)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to the filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act:

Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

The number of shares outstanding of the registrant's Common Stock, $0.001 par value, as of January 26, 2023 was 547,795,897.

MICROCHIP TECHNOLOGY INCORPORATED AND SUBSIDIARIES

INDEX

PART I. FINANCIAL INFORMATION
Item 1.Financial Statements (Unaudited)
Condensed Consolidated Balance Sheets – December 31, 2022 and March 31, 20224
Condensed Consolidated Statements of Income – Three and Nine Months Ended December 31, 2022 and 20215
Condensed Consolidated Statements of Comprehensive Income – Three and Nine Months Ended December 31, 2022 and 20216
Condensed Consolidated Statements of Cash Flows – Nine Months Ended December 31, 2022 and 20217
Condensed Consolidated Statements of Changes in Equity - Three and Nine Months Ended December 31, 2022 and 20218
Notes to Condensed Consolidated Financial Statements10
Item 2.Management's Discussion and Analysis of Financial Condition and Results of Operations24
Item 3.Quantitative and Qualitative Disclosures About Market Risk35
Item 4.Controls and Procedures36
PART II. OTHER INFORMATION
Item 1.Legal Proceedings37
Item 1A.Risk Factors37
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds56
Item 3.Defaults Upon Senior Securities56
Item 4.Mine Safety Disclosures56
Item 5.Other Information56
Item 6.Exhibits57
Signatures

MICROCHIP TECHNOLOGY INCORPORATED AND SUBSIDIARIES

Defined Terms(1)

TermDefinition
4.333% 2023 Notes2023 Senior Unsecured Notes, maturing June 1, 2023
2.670% 2023 Notes2023 Senior Unsecured Notes, maturing September 1, 2023
0.972% 2024 Notes2024 Senior Unsecured Notes, maturing February 15, 2024
0.983% 2024 Notes2024 Senior Unsecured Notes, maturing September 1, 2024
4.250% 2025 Notes2025 Senior Unsecured Notes, maturing September 1, 2025
2015 Senior Convertible Debt2015 Senior Convertible Debt, maturing February 15, 2025
2017 Senior Convertible Debt2017 Senior Convertible Debt, maturing February 15, 2027
2020 Senior Convertible Debt2020 Senior Convertible Debt, maturing November 15, 2024
2017 Junior Convertible Debt2017 Junior Convertible Debt, maturing February 15, 2037
ASUAccounting Standards Update
CEMsClient engagement managers
CHIPS ActCHIPS and Science Act of 2022
Convertible Debt2015 Senior Convertible Debt, 2017 Senior Convertible Debt, 2020 Senior Convertible Debt, and 2017 Junior Convertible Debt
Credit AgreementAmended and Restated Credit Agreement, dated as of December 16, 2021, among the Company, as borrower, the lenders from time to time party thereto, and J.P. Morgan Chase Bank, N.A., as administrative agent
EARExport Administration Regulation
ESEsEmbedded solutions engineers
Exchange ActSecurities Exchange Act of 1934, as amended
FASBFinancial Accounting Standards Board
FPGAField-programmable gate array
OEMsOriginal equipment manufacturers
R&DResearch and development
Revolving Credit Facility$2.75 billion revolving credit facility created pursuant to the Credit Agreement
RSUsRestricted stock units
SARsStock appreciation rights
SECU.S. Securities and Exchange Commission
Senior IndebtednessRevolving Credit Facility, 3.922% 2021 Notes, 4.333% 2023 Notes, 2.670% 2023 Notes, 0.972% 2024 Notes, 0.983% 2024 Notes, and 4.250% 2025 Notes
Senior Notes3.922% 2021 Notes, 4.333% 2023 Notes, 2.670% 2023 Notes, 0.972% 2024 Notes, 0.983% 2024 Notes, and 4.250% 2025 Notes
TCJATax Cuts and Jobs Act of 2017
U.S. GAAPU.S. Generally Accepted Accounting Principles

(1) Certain terms used within this Form 10-Q are defined in the above table.

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. . Financial Statements

MICROCHIP TECHNOLOGY INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(in millions, except share and per share amounts; unaudited)

ASSETS
December 31,March 31,
20222022
Cash and cash equivalents$288.9$317.4
Short-term investments—2.0
Accounts receivable, net1,175.01,072.6
Inventories1,165.4854.4
Other current assets204.4206.2
Total current assets2,833.72,452.6
Property, plant and equipment, net1,113.7967.9
Goodwill6,673.66,673.6
Intangible assets, net3,544.84,043.1
Long-term deferred tax assets1,630.01,797.1
Other assets320.3265.2
Total assets$16,116.1$16,199.5
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable$354.8$344.7
Accrued liabilities1,256.31,054.3
Total current liabilities1,611.11,399.0
Long-term debt6,588.77,687.4
Long-term income tax payable660.3704.6
Long-term deferred tax liability40.339.8
Other long-term liabilities904.1473.9
Stockholders' equity:
Preferred stock, $0.001 par value; authorized 5,000,000 shares; no shares issued or outstanding——
Common stock, $0.001 par value; authorized 900,000,000 shares; 577,805,496 shares issued and 547,792,012 shares outstanding at December 31, 2022; 577,805,396 shares issued and 554,500,524 shares outstanding at March 31, 20220.50.6
Additional paid-in capital2,380.42,535.9
Common stock held in treasury: 30,013,484 shares at December 31, 2022; 23,304,872 shares at March 31, 2022(1,407.8)(796.3)
Accumulated other comprehensive loss(17.5)(20.6)
Retained earnings5,356.04,175.2
Total stockholders' equity6,311.65,894.8
Total liabilities and stockholders' equity$16,116.1$16,199.5

See accompanying notes to condensed consolidated financial statements

Table of Contents

MICROCHIP TECHNOLOGY INCORPORATED AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(in millions, except per share amounts; unaudited)

Three Months Ended December 31,Nine Months Ended December 31,
2022202120222021
Net sales$2,169.2$1,757.5$6,206.0$4,976.7
Cost of sales698.4604.22,027.41,747.5
Gross profit1,470.81,153.34,178.63,229.2
Research and development282.4245.4820.0730.0
Selling, general and administrative202.9177.5594.2531.7
Amortization of acquired intangible assets167.4215.7502.5647.0
Special charges (income) and other, net6.5(0.3)(6.1)20.4
Operating expenses659.2638.31,910.61,929.1
Operating income811.6515.02,268.01,300.1
Interest income0.80.11.10.5
Interest expense(52.8)(62.1)(156.4)(199.2)
Loss on settlement of debt—(16.1)(8.3)(101.6)
Other income, net2.64.63.53.5
Income before income taxes762.2441.52,107.91,003.3
Income tax provision181.988.7474.2155.7
Net income$580.3$352.8$1,633.7$847.6

Showing the first 8K of 126K characters. Open the full section

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Note Regarding Forward-looking Statements

This report, including "Part I – Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Part II - Item 1A. Risk Factors" contains certain forward-looking statements that involve risks and uncertainties, including statements regarding our strategy, financial performance and revenue sources. We use words such as "anticipate," "believe," "can," "continue," "could," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. Our actual results could differ materially from the results anticipated in these forward-looking statements as a result of certain factors including those set forth under "Risk Factors," beginning at page 37 and elsewhere in this Form 10-Q. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. You should not place undue reliance on these forward-looking statements. We disclaim any obligation to update information contained in any forward-looking statement. These forward-looking statements include, without limitation, statements regarding the following:

  • Our expectation that certain supply chain constraints will continue through much of calendar 2023;

  • That local governments could require us or our suppliers to reduce production, cease operations, or implement mandatory vaccine requirements, and we could experience constraints in fulfilling customer orders;

  • Our expectation that we will experience period-to-period fluctuations in operating results due to general industry or economic conditions;

  • The effects that uncertain global economic conditions and fluctuations in the global credit and equity markets may have on our financial condition and results of operations;

  • The effects and amount of competitive pricing pressure on our product lines and modest pricing declines in certain of our more mature proprietary product lines;

  • Our ability to moderate future average selling price declines;

  • The effect of product mix, capacity utilization, yields, fixed cost absorption, competition and economic conditions on gross margin;

  • The amount of, and changes in, demand for our products and those of our customers;

  • The impact of national security protections, trade restrictions and changes in tariffs, including those impacting China;

  • Our expectation that in the future we will acquire additional businesses that we believe will complement our existing businesses;

  • Our expectation that in the future we will enter into joint development agreements or other strategic relationships with other companies;

  • The level of orders that will be received and shipped within a quarter, including the impact of our product lead times;

  • Our intent to vigorously defend our legal positions;

  • Our goal to continue to be more efficient with our selling, general and administrative expenses;

  • Our expectation that our days of inventory at March 31, 2023 will be 157 to 164 days;

  • Our belief that customers recognize our products and brand name and use distributors as an effective supply channel;

  • The accuracy of our estimates of the useful life and values of our property, assets and other liabilities;

  • Our ability to increase the proprietary portion of our analog product line and the effect of such an increase;

  • The impact of any supply disruption we may experience;

  • Our ability to effectively utilize our facilities at appropriate capacity levels;

  • The likelihood of our stock price to fluctuate in the future;

  • Our ability to maintain manufacturing yields;

  • The maintenance of our competitive position based on our investments in new and enhanced products;

  • The success of our licensing business depending on the continued market acceptance of our technologies and on our ability to further develop such technologies and to introduce new technologies;

  • The potential of the Preferred Supply Program and the long-term supply agreements to satisfy commitments to our suppliers, enable us to forecast capital equipment requirements and employee needs, ramp up manufacturing and manufacture products more efficiently;

  • The cost effectiveness of using our own assembly and test operations;

  • The greater functionality in new product designs afforded by our proprietary design and manufacturing processes;

  • Our plans to continue to transition certain outsourced assembly and test capacity to our internal facilities;

  • Our expectation of continued investment in expanding our manufacturing capacity through calendar 2023 and during the next twelve months;

  • The continued development of the embedded control market based on our strong technical service presence;

Table of Contents

  • Our expectation that foundry capacity will continue to be limited due to strong demand for wafers across the industry;

  • Our expectation that we will continue to operate our manufacturing facilities at or above normal capacity if the current supply constraints relative to demand continue;

  • Our anticipated level of capital expenditures;

  • Our expectations regarding cash inflows and outflows under our long-term supply arrangements;

  • The continuation and amount of quarterly cash dividends;

  • The sufficiency of our existing sources of liquidity to finance anticipated capital expenditures and otherwise meet our anticipated cash requirements, and the effects that our contractual obligations are expected to have on them;

  • Our belief that the capital expenditures to be incurred over the next twelve months will provide sufficient manufacturing capacity to support the growth of our production capabilities for our new products and technologies and to bring in-house more of the production requirements that are currently outsourced;

  • The impact of seasonality on our business;

  • Our belief that our IT system compromise has not had a material adverse effect on our business or resulted in any material damage to us;

  • Our expectation that we will continue to be the target of cyber-attacks, computer viruses, unauthorized access and other attempts to breach or otherwise compromise the security of our IT systems and data;

  • The impact of the resolution of legal actions on our business, and the accuracy of our assessment of the probability of loss and range of potential loss;

  • Our plans to pursue all available administrative and judicial remedies necessary to resolve the Statutory Notice of Deficiency we received;

  • Our expectation regarding the treatment of our unrecognized tax benefits in calendar year 2023;

  • Our belief that the expiration of any tax holidays will not have a material impact on our effective tax rate;

  • The impact of the geographical dispersion of our earnings and losses on our effective tax rate;

  • Our belief that the estimates used in preparing our condensed consolidated financial statements are reasonable;

  • Our actions to vigorously and aggressively defend and protect our intellectual property on a worldwide basis;

  • Our ability to obtain patents and intellectual property licenses and minimize the effects of litigation;

  • The level of risk we are exposed to for product liability claims or indemnification claims;

  • The effect of fluctuations in market interest rates on our income and/or cash flows;

  • The effect of fluctuations in currency rates;

  • Our ability to increase our borrowings or seek additional equity or debt financing to maintain or expand our facilities, or to fund cash dividends, share repurchases, acquisitions or other corporate activities, and that the timing and amount of such financing requirements will depend on a number of factors;

  • Our expectations regarding the amounts and timing of repurchases under our stock repurchase program;

  • Our expectation that our reliance on th

Showing the first 8K of 64K characters. Open the full section

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As of December 31, 2022, our long-term debt totaled $6.62 billion. We have no interest rate exposure to rate changes on our fixed rate debt, which totaled $6.37 billion as of December 31, 2022. We have interest rate exposure with respect to the $253.0 million of our variable interest rate debt outstanding under our Revolving Credit Facility as of December 31, 2022. A 50-basis point increase in interest rates would impact our expected annual interest expense for the next 12 months by approximately $1.3 million.

Table of Contents

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report on Form 10-Q, as required by paragraph (b) of Rule 13a-15 or Rule 15d-15 under the Exchange Act, we evaluated under the supervision of our Chief Executive Officer and our Chief Financial Officer, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) of the Exchange Act). Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective to ensure that information we are required to disclose in reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms, and (ii) is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Our disclosure controls and procedures are designed to provide reasonable assurance that such information is accumulated and communicated to our management. Our disclosure controls and procedures include components of our internal control over financial reporting. Management's assessment of the effectiveness of our internal control over financial reporting is expressed at the level of reasonable assurance because a control system, no matter how well designed and operated, can provide only reasonable, but not absolute, assurance that the control system's objectives will be met.

Changes in Internal Control over Financial Reporting

During the three months ended December 31, 2022, there was no change in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 or Rule 15d-15 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

Refer to "Note 11. Commitments and Contingencies" to our condensed consolidated financial statements for information regarding legal proceedings.

Item 1A. Risk Factors

When evaluating Microchip and its business, you should give careful consideration to the factors below, as well as the information provided elsewhere in this Form 10-Q and in other filings we make with the SEC.

Risk Factor Summary

Risks Related to Our Business, Operations, and Industry

  • impact of global economic conditions on our operating results, net sales and profitability;

  • impact of economic conditions on the financial viability of our licensees, customers, distributors, or suppliers;

  • impact of the COVID-19 pandemic, increased tariffs or other factors affecting our suppliers;

  • dependency on wafer foundries and other contractors by our licensees and ourselves;

  • dependence on foreign sales, suppliers, and operations, which exposes us to foreign political and economic risks;

  • limited visibility to product shipments;

  • intense competition in the markets we serve, leading to pricing pressures, reduced sales or market share;

  • ineffective utilization of our manufacturing capacity or failure to maintain manufacturing yields;

  • impact of seasonality and wide fluctuations of supply and demand in the industry;

  • dependency on distributors;

  • ability to introduce new products on a timely basis;

  • business interruptions, including natural disasters, affecting our operations or that of key vendors, licensees or customers;

  • technology licensing business exposes us to various risks;

  • reliance on sales into governmental projects, and compliance with associated regulations;

  • risks related to grants from governments, agencies and research organizations;

  • future acquisitions or divestitures;

  • future impairments to goodwill or intangible assets;

  • our failure to maintain proper and effective internal control and remediate future control deficiencies;

  • customer demands to implement business practices that are more stringent than legal requirements;

  • ability to attract and retain qualified personnel; and

  • the occurrence of events for which we are self-insured, or which exceed our insurance limits.

Risks Related to Cybersecurity, Privacy, Intellectual Property, and Litigation

  • attacks on our IT systems, interruptions in our IT systems, or improper handling of data;

  • risks related to compliance with privacy and data protection laws and regulations;

  • risks related to legal proceedings, investigations or claims;

  • risks related to contractual relationships with our customers; and

  • protecting and enforcing our intellectual property rights.

Risks Related to Taxation, Laws and Regulations

  • impact of new accounting pronouncements or changes in existing accounting standards and practices;

  • fines, restrictions or delay in our ability to export or import products, or increase costs associated with the manufacture or transfer of products;

  • outcome of future examinations of our income tax returns;

  • exposure to greater than anticipated income tax liabilities, changes in or the interpretation of tax rules and regulations including the TCJA, the American Rescue Plan Act of 2021 (ARPA), or unfavorable assessments from tax audits;

  • impact of the legislative and policy changes implemented globally by the current or future administrations;

  • impact of stringent environmental, climate change, conflict-free minerals and other regulations or customer demands; and

  • requirement to fund our foreign pension plans.

Table of Contents

Risks Related to Capitalization and Financial Markets

  • impact of various factors on our future trading price of our common stock;

  • fluctuations in the amount and timing of our common stock repurchases;

  • our ability to effectively manage current or future debt;

  • our ability to generate sufficient cash flows or obtain access to external financing;

  • impact of conversion of our convertible debt on the ownership interest of our existing stockholders; and

  • fluctuations in foreign currency exchange rates.

Risks Related to Our Business, Operations, and Industry

Our operating results are impacted by global economic conditions and may fluctuate in the future due to a number of factors that could reduce our net sales and profitability.

Our operating results are affected by a wide variety of factors that could reduce our net sales and profitability, many of which are beyond our control. Some of the factors that may affect our operating results include:

  • general economic, industry, public health or political conditions in the U.S. or internationally, including uncertain economic conditions in U.S., China and Europe, increases in interest rates, high inflation or further uncertainty surrounding the COVID-19 pandemic and its implications;

  • disruptions in our business, our supply chain or our customers' businesses due to public health concerns (including viral outbreaks such as COVID-19), cybersecurity incidents, terrorist activity, armed conflict, war (including Russia's invasion of Ukraine), worldwide oil prices and supply, fires, natural disasters or disruptions in the transportation system;

  • availability of raw materials including rare earth minerals, supplies and equipment due to supply chain constraints or other factors;

  • constrained availability from other electronic suppliers impacting our customers' ability to ship their products, which in turn may adversely impact our sales to those customers;

  • our ability to continue to increase our factory capacity to respond to changes in customer demand;

  • our ability to secure sufficient wafer foundry, assembly and testing capacity;

  • increased costs and availability of raw materials, supplies, equipment, utilities, labor, and/or subcontracted services for wafers, assembly and test;

  • changes in demand or market acceptance of our products and products of our customers, and market fluctuations in the industries into which such products are sold;

  • the level of order cancellations or push-outs due to the impact of the COVID-19 pandemic or other factors;

  • trade restrictions and increase in tariffs, including those on business in China, or focused on specific companies;

  • the mix of inventory we hold and our ability to satisfy orders from our inventory;

  • changes in utilization of our manufacturing capacity and fluctuations in manufacturing yields;

  • changes or fluctuations in customer order patterns and seasonality;

  • changes in tax regulations in countries in which we do business;

  • new accounting pronouncements or changes in existing accounting standards and practices;

  • levels of inventories held by our customers and the customers of our distributors;

  • risk of excess and obsolete inventories;

  • competitive developments including pricing pressures;

  • unauthorized copying of our products resulting in pricing pressure and loss of sales;

  • our ability to successfully transition to more advanced process technologies to reduce manufacturing costs;

  • the level of orders that are received and can be shipped in a quarter, including the impact of product lead times;

  • the level of sell-through of our products through distribution;

  • our ability to continue to realize the expected benefits of our past or future acquisitions;

  • fluctuations in our mix of product sales;

  • announcements of other significant acquisitions by us or our competitors;

  • costs and outcomes of any current or future tax audits or any litigation, investigation or claims involving intellectual property, our Microsemi acquisition, customers or other issues; and

  • property damage or other losses, whether or not covered by insurance.

Period-to-period comparisons of our operating results are not necessarily meaningful and you should not rely upon any such comparisons as indications of our future performance. In future periods, our operating results may fall below our public guidance or the expectations of public market analysts and investors, which would likely have a negative effect on the pri

Showing the first 8K of 111K characters. Open the full section

Item 5. Other Information

Item 6. Exhibits

Incorporated by Reference
Exhibit NumberExhibit DescriptionFormFile NumberExhibitFiling DateIncluded Herewith
3.1Amended and Restated Certificate of Incorporation of Microchip Technology Incorporated8-K000-211843.1August 26, 2021
3.2Amended and Restated Bylaws of Registrant, as amended effective May 25, 20218-K000-211843.1May 28, 2021
10.1*Amended and Restated Form of Notice of Grant of Restricted Stock Units (Performance) for 2004 Equity Incentive Plan (including Exhibit A Performance Matrix)X
31.1Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as amendedX
31.2Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as amendedX
32**Certifications Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002X
101.INSInline XBRL Instance Document - the instance document does not appear in the Interactive File because its XBRL tags are embedded within the Inline XBRL documentX
101.SCHInline XBRL Taxonomy Extension Schema DocumentX
101.CALInline XBRL Taxonomy Extension Calculation Linkbase DocumentX
101.DEFInline XBRL Taxonomy Extension Definition Linkbase DocumentX
101.LABInline XBRL Taxonomy Extension Label Linkbase DocumentX
101.PREInline XBRL Taxonomy Extension Presentation Linkbase DocumentX
104Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document or included within the Exhibit 101 attachmentsX
  • Compensation plans or arrangements in which directors or executive officers are eligible to participate

** This certification is being furnished solely to accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

MICROCHIP TECHNOLOGY INCORPORATED
Date:February 2, 2023By: /s/ J. Eric Bjornholt
J. Eric Bjornholt
Senior Vice President and Chief Financial Officer
(Duly Authorized Officer, and Principal Financial and Accounting Officer)